We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
RE-ASVI/ MNTX Well that didn't take long from my last post. I absolutely love what the board decided to do with their ASVI stake.
IMO restores much value back to the company. This with my take of straight mask cranes, and my personal take, of not being a strict constructionist (pun intended) on value stock buys.
Upon successful IPO completion. Future catalyst- Debt levels should sink as well as quarterly interest payments. A reduced debt level is also a positive selling point among potential buyers of their products. IMO This makes the IPO a future target itself. This scenario with TEX approval. This puts CAT into play as a future niche possible hypothetical buyer for ASV. IMO this move also makes MNTX a more of a speculative target. Failed TEX bidder ZOOMLION once again comes to mind. I can still see ZL being interested in the US infrastructure market. This would make it smaller, but a more affordable way to participate. It also would mostly likely not be in the selling to China political limelight like the failed TEX deal was.
Sold SITT # 1 weighted position in INCR today. The company's coming merger 75 million break up fee clause. Scares possible hypothetical suitors of INCR. Plus the costs associated with the merger. IMO make it near term fully valued fundamentally . Another 5% gain on top of the merger announcement gain made it to tempting to hold.
Speculating in Takeover Targets | Stock Discussion ForumsShare
Colgate-Palmolive’s chief executive recently signaled he would be open to selling the company — which has grappled with sluggish demand for its toothpaste, deodorants and food products — for $100 a share, a source told The Post.